Aptose Biosciences Inc's Competitiveness

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

Company	Market Cap	Revenues	Income	Employees
Aptose Biosciences Inc	4.36	-	-27.56	14
Astrazeneca Plc	288,001.56	58,739.00	10,233.00	83,100
Amgen Inc	255,014.76	38,903.00	9,391.00	13,000
Gilead Sciences Inc	210,105.45	30,988.00	-3,863.00	17,000
Beone Medicines Ltd	47,513.48	6,606.28	915.57	12,000
Revolution Medicines Inc	37,191.09	29.51	-1,768.28	883
SUBTOTAL	880,170.89	142,557.31	13,697.82	130,920

Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on: November 13, 2026
Focus of this report: publicly traded companies. Ten additional tables on Aptose Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.

Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

Aptose Biosciences Inc ranks #0 of 157 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,443, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).

Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-04-01.

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Aptose Biosciences Inc's dedicated Suppliers and Customers pages, not here.

Methodology: see Methodology: SWOT Analysis.

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.